Wednesday, 29 August 2018 06:45

Appendix 4E and Preliminary Financial Report

Download attachments: Download PDF

 
Tuesday, 21 August 2018 07:54

CLINUVEL Investor Summary

Download attachments: 20180821InvestorSummary.pdf

 
Monday, 30 July 2018 07:30

Appendix 4C

Appendix 4C Melbourne, Australia and Leatherhead, UK, 30 July 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow report for the period 01 […]

 
Friday, 27 July 2018 07:03

CLINUVEL Newsletter – July 2018

Download attachments: 20180727_Newsletter.pdf

 
Tuesday, 17 July 2018 07:58

Change in substantial holding

Change in substantial holding Download attachments: 20180717Form604_FIL.pdf

 
Friday, 06 July 2018 09:13

Change in Director’s Interest Notice

Download attachments: 20180706App3YWB.pdf

 
Wednesday, 04 July 2018 10:11

Change in substantial holding

Change in substantial holding Download attachments: 20180704Form604_Lagoda.pdf

 
Monday, 25 June 2018 12:00

CLINUVEL COMPLETES SCENESSE® FDA FILING

Historic New Drug Application for the use of SCENESSE® in rare metabolic disorder EPP EXECUTIVE SUMMARY First NDA for SCENESSE® (afamelanotide 16mg) in the United States First-line therapy proposed as systemic photoprotection for EPP patients Submission of data from five clinical trials in EPP, pooled data, Compassionate Use, Special Access Schemes, and real-world experience from […]

 
Friday, 22 June 2018 12:05

Trading Halt

Request for trading haltDownload attachments: Download PDF

 
Friday, 01 June 2018 07:18

Appendix 3B

Appendix 3B Download attachments: 20180601App3B.pdf

 

NICE MAINTAINS ITS POSITION NOT TO RECOMMEND SCENESSE® FOR REIMBURSEMENTCLINUVEL TO APPEAL NICE DECISION IN ENGLANDMelbourne, Australia, and Leatherhead, UK, 23 May 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION: CLVLY) today announced that the English National Institute of Health and Care Excellence (NICE) maintained its position not to recommend CLINUVEL’s drug […]

 
Thursday, 17 May 2018 07:36

Change in substantial holding

Change in substantial holding Download attachments: 20180517Changeinsubstantialholding.pdf

 
Wednesday, 16 May 2018 08:06

Change in substantial holding

Change in substantial holding Download attachments: 20180516Changeinsubstantialholding.pdf

 
Monday, 14 May 2018 06:19

CLINUVEL REGULATORY UPDATE

CLINUVEL REGULATORY UPDATE EUROPEAN SAFETY DATA ADDS TO US FDA FILING (NDA) ? European Annual and Periodic Reports show positive benefit-risk and safety profile maintained? SCENESSE® implants administered globally to date: >5,100 (>4,000 to EPP patients)? >99% treatment compliance rate in European EPP population maintained? >85% of European patients on treatment consented to inclusion in […]

 
Tuesday, 01 May 2018 07:06

Change in substantial holding

Change in substantial holding Download attachments: 20180501NoticeofChangeofInterestsofSubstantialHolder.pdf